DAVID D MORRISSEY, M.D.
Medical Practice at Arapahoe Ave, Boulder, CO
License number
Colorado 37667
Category
Medical Practice
Type
Otolaryngology
Address
Address
4745 Arapahoe Ave STE 130, Boulder, CO 80303
Phone
(303) 443-2771
(303) 443-2784 (Fax)
(303) 443-2784 (Fax)
Personal information
See more information about DAVID D MORRISSEY at radaris.comName
Address
Phone
557 Pine Dr, Windsor, CO 80550
645 Eldorado Blvd APT 1222, Broomfield, CO 80021
6383 Secrest St, Arvada, CO 80403
525 Mohawk Dr APT 1, Boulder, CO 80303
6776 S Ivy St APT A2, Centennial, CO 80112
Professional information
Dr. David D Morrissey - MD (Doctor of Medicine)
Procedures:
Septoplasty, Head/Neck Surgery, Tonsillectomy, Nasal/Sinus Surgery, Adenoidectomy, Facial Reconstructive Surgery (Accidents, Skin Cancers & Other Traumas), Sleep Apnea Surgery, balloon sinuplasty, Sinus Endoscopic Surgery, Nose Surgery (Rhinoplasty)
Hospitals:
Boulder Office
4745 Arapahoe Ave SUITE 130, Boulder 80303
Exempla Office
300 Exempla Cir SUITE 210, Lafayette 80026
Avista Office
90 Health Park Dr SUITE 220, Louisville 80027
Avista Adventist Hospital
100 Health Park Dr, Louisville 80027
Boulder Community Hospital
1100 Balsam Ave, Boulder 80301
Exempla Good Samaritan Medical Center
200 Exempla Cir, Lafayette 80026
Boulder Office
4745 Arapahoe Ave SUITE 130, Boulder 80303
Exempla Office
300 Exempla Cir SUITE 210, Lafayette 80026
Avista Office
90 Health Park Dr SUITE 220, Louisville 80027
Avista Adventist Hospital
100 Health Park Dr, Louisville 80027
Boulder Community Hospital
1100 Balsam Ave, Boulder 80301
Exempla Good Samaritan Medical Center
200 Exempla Cir, Lafayette 80026
4745 Arapahoe Ave SUITE 130, Boulder 80303
Exempla Office
300 Exempla Cir SUITE 210, Lafayette 80026
Avista Office
90 Health Park Dr SUITE 220, Louisville 80027
Avista Adventist Hospital
100 Health Park Dr, Louisville 80027
Boulder Community Hospital
1100 Balsam Ave, Boulder 80301
Exempla Good Samaritan Medical Center
200 Exempla Cir, Lafayette 80026
Boulder Office
4745 Arapahoe Ave SUITE 130, Boulder 80303
Exempla Office
300 Exempla Cir SUITE 210, Lafayette 80026
Avista Office
90 Health Park Dr SUITE 220, Louisville 80027
Avista Adventist Hospital
100 Health Park Dr, Louisville 80027
Boulder Community Hospital
1100 Balsam Ave, Boulder 80301
Exempla Good Samaritan Medical Center
200 Exempla Cir, Lafayette 80026
Education:
Medical Schools
Univ Of Co Sch Of Med
Graduated: 1994
Univ Of Co Sch Of Med
Graduated: 1994
David D Morrissey, Boulder CO
Specialties:
Ear, Nose & Throat Doctor
Address:
4745 Arapahoe Ave, Boulder, CO 80303
Education:
University of Colorado, School of Medicine (Denver) - Doctor of Medicine
OHSU Hospitals & Clinics - Residency - Otolaryngology-Head and Neck Surgery
OHSU Hospitals & Clinics - Residency - Otolaryngology-Head and Neck Surgery
Board certifications:
American Board of Otolaryngology Certification in Otolaryngology
David Dell Morrissey, Boulder CO
Specialties:
Otolaryngology, Pediatric Otolaryngology, Plastic Surgery within the Head & Neck
Work:
Boulder Valley ENT Associates
4745 Arapahoe Ave, Boulder, CO 80303 Boulder Valley Ear, Nose & Throat Associates
90 Health Park Dr, Louisville, CO 80027 Hans Lee MD Inc
2211 Mountain View Ave, Longmont, CO 80501
4745 Arapahoe Ave, Boulder, CO 80303 Boulder Valley Ear, Nose & Throat Associates
90 Health Park Dr, Louisville, CO 80027 Hans Lee MD Inc
2211 Mountain View Ave, Longmont, CO 80501
Education:
University of Colorado (1994) *, Oregon Health & Science University Hospitals And Clinics (1999) *Otolaryngology
Rna Inteference Mediated Inhibition Of Hepatitis C Virus (Hvc) Gene Expression Using Short Interfering Nucleic Acid (Sina)
US Patent:
2008020, Aug 28, 2008
Filed:
Aug 25, 2006
Appl. No.:
11/510872
Inventors:
James McSwiggen - Boulder CO, US
David Morrissey - Boulder CO, US
Roberto Guerciolini - Boulder CO, US
Chandra Vargeese - Broomfield CO, US
Vasant Jadhav - Longmont CO, US
David Morrissey - Boulder CO, US
Roberto Guerciolini - Boulder CO, US
Chandra Vargeese - Broomfield CO, US
Vasant Jadhav - Longmont CO, US
Assignee:
Sirna Therapeutics, Inc. - San Francisco CA
International Classification:
A61K 31/713
US Classification:
514 44
Abstract:
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules, such as endogenous micro-RNA (miRNA) (e.g, miRNA inhibitors) or endogenous short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC), including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules and are useful, for example, in providing compositions to prevent, inhibit, or reduce diseases, traits and conditions that are associated with gene expression or activity in a subject or organism.
Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
US Patent:
2006029, Dec 28, 2006
Filed:
Aug 11, 2006
Appl. No.:
11/502885
Inventors:
James McSwiggen - Boulder CO, US
Bharat Chowrira - Louisville CO, US
Leonid Beigelman - Brisbane CA, US
Dennis Macejak - Arvada CO, US
Shawn Zinnen - Denver CO, US
Pamela Pavco - Lafayette CO, US
Peter Haeberli - Berthoud CO, US
David Morrissey - Boulder CO, US
Kathy Fosnaugh - Boulder CO, US
Sharon Jamison - Boulder CO, US
Nassim Usman - Lafayette CO, US
James Thompson - Lafayette CO, US
Chandra Vargeese - Broomfield CO, US
Weimin Wang - Superior CO, US
Tongqian Chen - Longmont CO, US
Narendra Vaish - Denver CO, US
Bharat Chowrira - Louisville CO, US
Leonid Beigelman - Brisbane CA, US
Dennis Macejak - Arvada CO, US
Shawn Zinnen - Denver CO, US
Pamela Pavco - Lafayette CO, US
Peter Haeberli - Berthoud CO, US
David Morrissey - Boulder CO, US
Kathy Fosnaugh - Boulder CO, US
Sharon Jamison - Boulder CO, US
Nassim Usman - Lafayette CO, US
James Thompson - Lafayette CO, US
Chandra Vargeese - Broomfield CO, US
Weimin Wang - Superior CO, US
Tongqian Chen - Longmont CO, US
Narendra Vaish - Denver CO, US
Assignee:
Sirna Therapeutics, Inc. - San Francisco CA
International Classification:
A61K 48/00, C07H 21/02, C07F 9/6512
US Classification:
435325000, 514044000, 536023100, 544243000
Abstract:
The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
US Patent:
2007000, Jan 4, 2007
Filed:
Aug 4, 2006
Appl. No.:
11/499520
Inventors:
James McSwiggen - Boulder CO, US
Bharat Chowrira - Louisville CO, US
Leonid Beigelman - Brisbane CA, US
Dennis Macejak - Arvada CO, US
Shawn Zinnen - Denver CO, US
Pamela Pavco - Lafayette CO, US
Peter Haeberli - Berthoud CO, US
David Morrissey - Boulder CO, US
Kathy Fosnaugh - Boulder CO, US
Sharon Jamison - Boulder CO, US
Nassim Usman - Lafayette CO, US
James Thompson - Lafayette CO, US
Chandra Vargeese - Broomfield CO, US
Weimin Wang - Superior CO, US
Tongqian Chen - Longmont CO, US
Narendra Vaish - Denver CO, US
Bharat Chowrira - Louisville CO, US
Leonid Beigelman - Brisbane CA, US
Dennis Macejak - Arvada CO, US
Shawn Zinnen - Denver CO, US
Pamela Pavco - Lafayette CO, US
Peter Haeberli - Berthoud CO, US
David Morrissey - Boulder CO, US
Kathy Fosnaugh - Boulder CO, US
Sharon Jamison - Boulder CO, US
Nassim Usman - Lafayette CO, US
James Thompson - Lafayette CO, US
Chandra Vargeese - Broomfield CO, US
Weimin Wang - Superior CO, US
Tongqian Chen - Longmont CO, US
Narendra Vaish - Denver CO, US
Assignee:
Sirna Therapeutics, Inc. - San Francisco CA
International Classification:
A61K 48/00, C07H 21/02, C07F 9/6512
US Classification:
514044000, 536023100, 514081000, 544243000
Abstract:
The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
US Patent:
2007000, Jan 4, 2007
Filed:
Aug 4, 2006
Appl. No.:
11/499529
Inventors:
James McSwiggen - Boulder CO, US
Bharat Chowrira - Louisville CO, US
Leonid Beigelman - Brisbane CA, US
Dennis Macejak - Arvada CO, US
Shawn Zinnen - Denver CO, US
Pamela Pavco - Lafayette CO, US
Peter Haeberli - Berthoud CO, US
David Morrissey - Boulder CO, US
Kathy Fosnaugh - Boulder CO, US
Sharon Jamison - Boulder CO, US
Nassim Usman - Lafayette CO, US
James Thompson - Lafayette CO, US
Chandra Vargeese - Broomfield CO, US
Weimin Wang - Superior CO, US
Tongqian Chen - Longmont CO, US
Narendra Vaish - Denver CO, US
Bharat Chowrira - Louisville CO, US
Leonid Beigelman - Brisbane CA, US
Dennis Macejak - Arvada CO, US
Shawn Zinnen - Denver CO, US
Pamela Pavco - Lafayette CO, US
Peter Haeberli - Berthoud CO, US
David Morrissey - Boulder CO, US
Kathy Fosnaugh - Boulder CO, US
Sharon Jamison - Boulder CO, US
Nassim Usman - Lafayette CO, US
James Thompson - Lafayette CO, US
Chandra Vargeese - Broomfield CO, US
Weimin Wang - Superior CO, US
Tongqian Chen - Longmont CO, US
Narendra Vaish - Denver CO, US
Assignee:
Sirna Therapeutics, Inc. - San Francisco CA
International Classification:
A61K 48/00, C07H 21/02, C07F 9/6512
US Classification:
514044000, 514081000, 536023100, 544243000
Abstract:
The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
US Patent:
2005003, Feb 10, 2005
Filed:
Apr 16, 2004
Appl. No.:
10/826966
Inventors:
James McSwiggen - Boulder CO, US
Dennis Macejak - Arvada CO, US
David Morrissey - Boulder CO, US
Dennis Macejak - Arvada CO, US
David Morrissey - Boulder CO, US
Assignee:
Sirna Therapeutics, Inc. - Boulder CO
International Classification:
A61K048/00, C07H021/04
US Classification:
514044000, 536023720, 800003000
Abstract:
The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
US Patent:
2006024, Nov 2, 2006
Filed:
Feb 21, 2006
Appl. No.:
11/358540
Inventors:
James McSwiggen - Boulder CO, US
Bharat Chowrira - Louisville CO, US
Leonid Beigelman - Longmont CO, US
Dennis Macejak - Arvada CO, US
Shawn Zinnen - Denver CO, US
Pamela Pavco - Lafayette CO, US
Peter Haeberli - Berthoud CO, US
David Morrissey - Boulder CO, US
Kathy Fosnaugh - Boulder CO, US
Sharon Jamison - Boulder CO, US
Nassim Usman - Lafayette CO, US
James Thompson - Lafayette CO, US
Chandra Vargeese - Thorton CO, US
Weimin Wang - Superior CO, US
Tongqian Chen - Longmont CO, US
Narendra Vaish - Boulder CO, US
Bharat Chowrira - Louisville CO, US
Leonid Beigelman - Longmont CO, US
Dennis Macejak - Arvada CO, US
Shawn Zinnen - Denver CO, US
Pamela Pavco - Lafayette CO, US
Peter Haeberli - Berthoud CO, US
David Morrissey - Boulder CO, US
Kathy Fosnaugh - Boulder CO, US
Sharon Jamison - Boulder CO, US
Nassim Usman - Lafayette CO, US
James Thompson - Lafayette CO, US
Chandra Vargeese - Thorton CO, US
Weimin Wang - Superior CO, US
Tongqian Chen - Longmont CO, US
Narendra Vaish - Boulder CO, US
Assignee:
Sirna Therapeutics, Inc. - Boulder CO
International Classification:
C07H 21/02, C07F 9/6512
US Classification:
536023100, 544243000
Abstract:
The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
Nucleic Acid Mediated Inhibition Of Enterococcus Infection And Cytolysin Toxin Activity
US Patent:
2005020, Sep 22, 2005
Filed:
Dec 14, 2004
Appl. No.:
11/011913
Inventors:
David Morrissey - Boulder CO, US
Peter Haeberli - Berthoud CO, US
Peter Haeberli - Berthoud CO, US
Assignee:
Sirna Therapeutics, Inc. - Boulder CO
International Classification:
A61K048/00, C12Q001/68, C07H021/04, C12N009/99, C12N005/08
US Classification:
514044000, 536023200, 435069200, 435366000, 435184000
Abstract:
The present invention relates to nucleic acid aptamers that bind to bacterial proteases such as CylA and methods for their use alone or in combination with other therapies, such as antibiotics. Also disclosed are nucleic acids such as siRNA, antisense, and enzymatic nucleic acid molecules that can modulate the expression of CylA genes. The compounds and methods of the invention are expected to inhibit infection and cytolysin activity.